Shanghai, China and New Jersey, U.S., April 10, 2023—Specialty committees under the China Pharmaceutical Innovation and Research Development Association (PhIRDA) have recently held meetings for re-election or establishment. Below are the four experts from Laekna Therapeutics who have been elected members to the specialty committees:
● Dr. Yong Yue, Chief Medical Officer
Member of the Clinical Research on Oncology Drugs Specialty Committee
● Gary Wang, Vice President of Clinical Development
Member of the Medical Digitalization and Innovative Therapies Specialty Committee
● Huimin Chen, Head of Regulatory Affairs
Member of the Medicinal Policy Specialty Committee
● Emma Cao, Head of Pharmacovigilance
Member of the Clinical Research on Cardiovascular Drugs Specialty Committee
(From left: Huimin Chen, Gary Wang, Dr. Yong Yue, Emma Cao)
“We’re deeply honored to be elected members of PhIRDA’s specialty committees. This is a great honor not only for me and my colleagues, but also for Laekna Therapeutics. We will continue to work with our partners and industry experts to contribute to the industry,” said Dr. Yong Yue, CMO of Laekna Therapeutics.
Gary Wang was speaking at the China Biomed Innovation and Investment Conference on March 29, 2023.
About PhIRDA
Follow us on Linkedin